Goldman Sachs analyst David Roman lowered the firm’s price target on Edwards Lifesciences (EW) to $95 from $108 and keeps a Buy rating on the shares. The firm continues to see “multiple” upside drivers in 2026 and beyond, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $100 from $98 at Piper Sandler
- AtriCure downgraded to Neutral from Overweight at JPMorgan
- Closing Bell Movers: Robinhood slips 8% after revenue miss
- Edwards Lifesciences reports Q4 adjusted EPS 58c, consensus 62c
- Edwards Lifesciences sees Q1 adjusted EPS 70c-76c, consensus 69c